ArticleImaging neuroscience (Cambridge, Mass.)2025
On the validity of fMRI mega-analyses using data processed with different pipelines.
Article in Imaging neuroscience (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pipeline variability: Friend or foe, depending on the goal: Comment on Germani et al. 2025.Imaging neuroscience (Cambridge, Mass.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
In neuroimaging and functional magnetic resonance imaging (fMRI), many derived data are made openly available in public databases. These can be re-used to increase sample sizes in studies and thus, improve robustness. In fMRI studies, raw data are first preprocessed using a given analysis pipeline to obtain subject-level contrast maps, which are then combined into a group analysis. Typically, the subject-level analysis pipeline is identical for all participants. However, derived data shared on public databases often come from different workflows, which can lead to different results. Here, we investigate how this analytical variability, if not accounted for, can induce false positive detections in mega-analyses combining subject-level contrast maps processed with different pipelines. We use the Human Connectome Project (HCP) multi-pipeline dataset, containing contrast maps for N = 1,080 participants of the HCP Young-Adult dataset, whose raw data were processed and analyzed with 24 different pipelines. We performed between-groups analyses with contrast maps from different pipelines in each group and estimated the rates of pipeline-induced detections. We show that, if not accounted for, analytical variability can lead to inflated false positive rates in studies combining data from different pipelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.